Sandbox2: Difference between revisions
No edit summary |
→Initial Management: Characterize the symptoms |
||
Line 11: | Line 11: | ||
==Managment== | ==Managment== | ||
===Initial Management=== | ===Initial Management=== | ||
Shown below is an algorithm summarizing the initial | Shown below is an algorithm summarizing the initial aproach to [[Wolff-Parkinson-White syndrome]] according to the 2003 ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias.<ref name="circ.ahajournals.org">{{Cite web | last = | first = | title = ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias—Executive Summary | url = http://circ.ahajournals.org/content/108/15/1871 | publisher = | date = | accessdate = 15 August 2013 }}</ref> | ||
'''AVRT''': [[AV reentrant tachycardia]] | '''AVRT''': [[AV reentrant tachycardia]] | ||
Line 78: | Line 78: | ||
❑ Administration of [[Procainamide]], [[Flecainide]] or [[Ibutilide]] is the prefered treatment<br> | ❑ Administration of [[Procainamide]], [[Flecainide]] or [[Ibutilide]] is the prefered treatment<br> | ||
❑ [[Adenosine]] should be used with caution because may produce [[AF]]<br> | ❑ [[Adenosine]] should be used with caution because may produce [[AF]]<br> | ||
</div>}} | |||
{{familytree/end}} | |||
===[[Wolff-Parkinson-White syndrome]] with [[Atrial fibrillation]]=== | |||
Shown below is an algorithm summarizing the managment of [[Wolff-Parkinson-White syndrome]]with [[Atrial fibrillation]] according to the ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation.<ref name="Fuster-2006">{{Cite journal | last1 = Fuster | first1 = V. | last2 = Rydén | first2 = LE. | last3 = Cannom | first3 = DS. | last4 = Crijns | first4 = HJ. | last5 = Curtis | first5 = AB. | last6 = Ellenbogen | first6 = KA. | last7 = Halperin | first7 = JL. | last8 = Le Heuzey | first8 = JY. | last9 = Kay | first9 = GN. | title = ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. | journal = Circulation | volume = 114 | issue = 7 | pages = e257-354 | month = Aug | year = 2006 | doi = 10.1161/CIRCULATIONAHA.106.177292 | PMID = 16908781 }}</ref> | |||
{{familytree/start}} | |||
{{familytree | | | | | | | | | | A01 | | | | | | | | | A01=<div style="float: left; text-align: left; width: 27em; padding:1em;"><br> | |||
❑ Control ventricular response<br> | |||
❑ If possible: terminate [[AF]]<br> | |||
❑ Avoid AV blocking agents<br> | |||
</div>}} | |||
{{familytree | | | | | | | | | | |!| | | | | | |}} | |||
{{familytree | | | | | |,|-|-|-|-|^|-|-|-|-|.| |}} | |||
{{familytree | | | | | B01 | | | | | | | | B02 | B01=<div style="float: left; text-align: left;"> '''Stable patient'''<br> | |||
❑ Restore sinus rythm:<br> | |||
:❑ [[Ibutilide]]<br> | |||
:❑ [[Procainamide]]<br> | |||
:❑ In case of the drugs listed above are not available use [[Amiodarone]]<br> | |||
</div>}} | </div>}} | ||
{{familytree/end}} | {{familytree/end}} |
Revision as of 18:38, 17 March 2014
|
Overview
Wolff-Parkinson-White syndrome (WPW) is a syndrome of pre-excitation of the ventricles of the heart due to an accessory pathway known as the Bundle of Kent.
Causes
Life Threatening Causes
Life-threatening causes include conditions which result in death or permanent disability within 24 hours if left untreated. Wolff-Parkinson-White syndrome can be a life-threatening condition and must be treated as such irrespective of the underlying cause.
Common Causes
WPW is a congenic disease
Managment
Initial Management
Shown below is an algorithm summarizing the initial aproach to Wolff-Parkinson-White syndrome according to the 2003 ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias.[1]
AVRT: AV reentrant tachycardia
Characterize the symptoms:
Characterize the timing of the symptoms: | |||||||||||||||||||||||||||||||||||||||||||||||
Identify possible triggers: | |||||||||||||||||||||||||||||||||||||||||||||||
❑ Examine the patient
❑ Order and monitor the ECG | |||||||||||||||||||||||||||||||||||||||||||||||
Stable patient | Unstable patient | ||||||||||||||||||||||||||||||||||||||||||||||
❑ Assess the ECG | ❑ Urgent electrical cardioversion | ||||||||||||||||||||||||||||||||||||||||||||||
Orthodromic AVRT The impulse travels from the atrium to the ventricle through the AV node and returns to the atrium through the accesory pathway. 90-95% of WPW ❑ Narrow QRS complexes | Antidromic AVRT The impulse travels from the atrium to the ventricle through theaccesory pathway and from the ventricle to the atrium through the AV node. Less than 10% of WPW ❑ Wide QRS complexes | ||||||||||||||||||||||||||||||||||||||||||||||
Treatment.[2][3][4] ❑ Use Valsalva maneuvers | Treatment. ❑ Administration of Procainamide, Flecainide or Ibutilide is the prefered treatment | ||||||||||||||||||||||||||||||||||||||||||||||
Wolff-Parkinson-White syndrome with Atrial fibrillation
Shown below is an algorithm summarizing the managment of Wolff-Parkinson-White syndromewith Atrial fibrillation according to the ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation.[5]
❑ Control ventricular response | |||||||||||||||||||||||||||||||||||||||
Stable patient ❑ Restore sinus rythm:
| {{{ B02 }}} | ||||||||||||||||||||||||||||||||||||||
References
- ↑ "ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias—Executive Summary". Retrieved 15 August 2013.
- ↑ Mehta, D.; Wafa, S.; Ward, DE.; Camm, AJ. (1988). "Relative efficacy of various physical manoeuvres in the termination of junctional tachycardia". Lancet. 1 (8596): 1181–5. PMID 2897005. Unknown parameter
|month=
ignored (help) - ↑ Jackman, WM.; Friday, KJ.; Fitzgerald, DM.; Yeung-Lai-Wah, JA.; Lazzara, R. (1988). "Use of intracardiac recordings to determine the site of drug action in paroxysmal supraventricular tachycardia". Am J Cardiol. 62 (19): 8L–19L. PMID 3059792. Unknown parameter
|month=
ignored (help) - ↑ Sung, RJ.; Elser, B.; McAllister, RG. (1980). "Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations". Ann Intern Med. 93 (5): 682–9. PMID 7212475. Unknown parameter
|month=
ignored (help) - ↑ Fuster, V.; Rydén, LE.; Cannom, DS.; Crijns, HJ.; Curtis, AB.; Ellenbogen, KA.; Halperin, JL.; Le Heuzey, JY.; Kay, GN. (2006). "ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society". Circulation. 114 (7): e257–354. doi:10.1161/CIRCULATIONAHA.106.177292. PMID 16908781. Unknown parameter
|month=
ignored (help)